Evidence map›Paper›PMID 16186256›Full record

ArticleThe Journal of cell biology2005

Lithium induces autophagy by inhibiting inositol monophosphatase.

Sovan Sarkar, R Andres Floto, Zdenek Berger, Sara Imarisio, Axelle Cordenier, Matthieu Pasco, Lynnette J Cook, David C Rubinsztein

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of cell biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 503 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
503citing papers in PubMed, 2 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01379469 phase2terminatednot on this mapstarted 2012, after this paper: background citation

A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

TypeinterventionalSponsorWashington University School of MedicineRan2012 to 2017Enrolled20ConditionsAlpha-1-antitrypsin Deficiency, Liver CirrhosisArmsDrug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
NCT05221593 phase3completednot on this mapstarted 2020, after this paper: background citation

Evaluation of Lithium Efficacy Against Chemotherapy Induced Neutropenia in Breast Cancer Patients

TypeinterventionalSponsorAl-Azhar UniversityRan2020 to 2022Enrolled50ConditionsNeutropeniaArmsLithium Carbonate
3 · Its place in the literature

Who cites it

503 citing papers in PubMed, 2 syntheses or guidelines pooled it, 966 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

443 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sovan SarkarDepartment of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge CB2 2XY, England, UK.
R Andres Floto
Zdenek Berger
Sara Imarisio
Axelle Cordenier
Matthieu Pasco
Lynnette J Cook
David C Rubinsztein
Addenbrooke's Hospital · GBUniversity of Cambridge · GB

Funding

Medical Research Council G0000872Wellcome Trust
6 · The paper itself

Abstract

Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins. Currently, the only suitable pharmacologic strategy for up-regulating autophagy in mammalian cells is to use rapamycin, which inhibits the mammalian target of rapamycin (mTOR), a negative regulator of autophagy. Here we describe a novel mTOR-independent pathway that regulates autophagy. We show that lithium induces autophagy, and thereby, enhances the clearance of autophagy substrates, like mutant huntingtin and alpha-synucleins. This effect is not mediated by glycogen synthase kinase 3beta inhibition. The autophagy-enhancing properties of lithium were mediated by inhibition of inositol monophosphatase and led to free inositol depletion. This, in turn, decreased myo-inositol-1,4,5-triphosphate (IP3) levels. Our data suggest that the autophagy effect is mediated at the level of (or downstream of) lowered IP3, because it was abrogated by pharmacologic treatments that increased IP3. This novel pharmacologic strategy for autophagy induction is independent of mTOR, and may help treatment of neurodegenerative diseases, like Huntington's disease, where the toxic protein is an autophagy substrate.

Indexed as

alpha-SynucleinAnimalsAutophagyCell Line, TumorChlorocebus aethiopsCOS CellsEnzyme InhibitorsHumansHuntingtin ProteinInositolLithiumMutationNerve Tissue ProteinsNuclear ProteinsPhosphoric Monoester HydrolasesProtein Kinasesalpha-SynucleinEnzyme InhibitorsHTT protein, humanHuntingtin ProteinInositolLithiumMTOR protein, humanmyo-inositol-1 (or 4)-monophosphataseNerve Tissue ProteinsNuclear ProteinsPhosphoric Monoester HydrolasesProtein KinasesSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID16186256
PMCPMC2171537
OpenAlexW2098985594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.